Neurodegenerative diseases like Alzheimer's disease and Parkinson's disease represent some of the greatest challenges in modern medicine. While the underlying pathological mechanisms involve complex interactions between genetic susceptibility, protein aggregation, neuroinflammation, and cellular dysfunction, developing disease-modifying therapies has proven remarkably difficult. The failure of numerous high-profile clinical trials, particularly in Alzheimer's disease, has led to a fundamental rethinking of therapeutic strategies and an appreciation that multiple complementary approaches may be necessary[1].
The therapeutic landscape for neurodegenerative diseases has expanded dramatically in recent years, moving beyond symptomatic treatments toward disease-modifying approaches that target the core pathological processes. This page provides a comprehensive comparison of the major therapeutic modalities currently in development or clinical use, including antibody therapies, gene therapy, antisense oligonucleotides, small molecule drugs, cell therapy, and targeted protein degradation. Each modality offers distinct advantages and limitations, and the field is increasingly exploring combination approaches that may prove more effective than any single intervention[2].
Understanding the strengths and weaknesses of each therapeutic approach is essential for appreciating the current state of drug development and the challenges that remain. The choice of therapeutic modality depends on multiple factors, including the specific molecular target, the accessibility of the central nervous system, the nature of the disease pathology, and the stage of clinical development.
| Modality | Mechanism | Clinical Stage | Key Advantages | Key Limitations | Examples |
|---|---|---|---|---|---|
| Antibody Therapies | Bind and clear pathological proteins | Approved & Phase 3 | High specificity, proven in AD | High cost, peripheral administration, ARIA risk | Lecanemab, Donanemab, Prasinezumab |
| Gene Therapy | Deliver genetic material to modify cellular function | Phase 1/2 | Potential for long-term effect | Delivery challenges, immune response, safety | AAV-GRN, AAV-GAA |
| ASOs | Modulate RNA splicing/protein production | Approved & Phase 3 | Precise target engagement, CNS delivery | Off-target effects, repeat dosing | Tofersen, IONIS-MAPTRx |
| Small Molecules | Inhibit or modulate protein function | Approved & Phase 2/3 | Oral bioavailability, BBB penetration | Lower specificity, toxicity | BACE inhibitors, LRRK2 inhibitors |
| Cell Therapy | Replace lost neurons/support cells | Phase 1/2 | Potential for regeneration | Immune rejection, tumor risk, delivery | iPSC-derived neurons |
| Targeted Protein Degradation | Eliminate specific proteins via proteasome | Preclinical/Phase 1 | Novel mechanism, substoichiometric | Limited CNS delivery, new modality risks | PROTACs, molecular glues |
Antibody therapies leverage the immune system to target and clear pathological proteins that accumulate in neurodegenerative diseases. Monoclonal antibodies are designed to bind specifically to target proteins such as amyloid-beta, tau, or alpha-synuclein, marking them for clearance by the immune system[3]. This approach has shown significant promise in Alzheimer's disease, with two antibodies—lecanemab and donanemab—receiving regulatory approval in 2023 and 2024 respectively.
The therapeutic antibody approaches can be categorized by their target:
The field of antibody therapeutics for neurodegeneration has reached a critical milestone with the approval of lecanemab (Leqembi) and dononemab (Kisunla) for early Alzheimer's disease. These approvals represent the first disease-modifying therapies for Alzheimer's and validate the amyloid hypothesis, though they come with important limitations and safety concerns[4].
Key programs in clinical development include:
Major pharmaceutical companies advancing antibody therapies include:
Antibody therapies offer several significant advantages:
Despite their promise, antibody therapies face important challenges:
Gene therapy involves delivering genetic material into target cells to either:
The most common delivery vehicles are adeno-associated viruses (AAV), which can transduce post-mitotic neurons, persist for extended periods without integrating into the host genome, and have relatively low immunogenicity.
Gene therapy for neurodegenerative diseases remains largely in early-stage development, with several programs in Phase 1 and Phase 2 trials. The field has been advanced by successes in other neurological conditions, particularly spinal muscular atrophy with onasemnogene abeparvovec (Zolgensma) and various AAV programs for rare metabolic disorders[7].
Key programs in development include:
Companies advancing gene therapy for neurodegeneration include:
Gene therapy offers unique advantages:
Significant challenges remain:
Antisense oligonucleotides are short, synthetic single-stranded DNA sequences that bind to specific messenger RNA (mRNA) targets via Watson-Crick base pairing. This binding either:
ASOs can reduce production of disease-causing proteins, restore normal splicing patterns, or increase expression of protective protein variants. The technology has proven particularly valuable for neurological diseases where reducing a toxic protein can provide clinical benefit.
ASO therapy has achieved clinical success in several neurodegenerative diseases, with tofersen (Qalsody) receiving FDA approval in 2023 for SOD1-associated amyotrophic lateral sclerosis[9]. This approval represents a major milestone for the modality and validates the approach for targeting neurodegenerative proteins.
Key programs in development include:
The ASO field is dominated by a few key players:
ASO therapies offer distinctive benefits:
Challenges that remain include:
Small molecule drugs are low-molecular-weight compounds (typically <500 Da) that can penetrate the blood-brain barrier and modulate the activity of specific protein targets. In neurodegeneration, small molecules target various aspects of disease pathogenesis[11]:
Small molecules remain the most common therapeutic approach and include the only approved disease-modifying treatments for Parkinson's disease (MAO-B inhibitors provide modest symptomatic benefit). Recent developments include:
Approved treatments:
In development:
Major pharmaceutical companies with small molecule programs include:
Small molecules offer several practical advantages:
Key limitations include:
Cell therapy involves transplanting living cells into patients to replace lost neurons, provide trophic support, or modulate the immune system. The field has evolved from early transplant approaches using fetal tissue to contemporary strategies using stem cell-derived populations[14]:
Cell therapy for neurodegeneration is still in early-stage clinical development, with most programs in Phase 1 or Phase 2. The field has been advanced by successes in other areas, particularly hematopoietic stem cell transplantation and CAR-T cell therapy.
Key programs include:
Companies advancing cell therapy include:
Cell therapy offers unique mechanisms:
Significant scientific and practical challenges:
Targeted protein degradation is an emerging therapeutic modality that eliminates specific proteins by hijacking the cell's natural degradation machinery. The two main approaches are[15]:
PROTACs (Proteolysis-Targeting Chimeras): Bifunctional molecules with one domain binding the target protein and another binding an E3 ubiquitin ligase. This brings the target into proximity for ubiquitination and subsequent degradation by the proteasome.
Molecular glues: Small molecules that stabilize interactions between a target protein and an E3 ligase, leading to degradation. These are typically monovalent and can induce degradation without the bivalent architecture of PROTACs.
Targeted protein degradation is the newest modality in the neurodegeneration space, with most programs still in preclinical development. However, the technology has achieved multiple approvals in oncology (lenalidomide, pomalidomide, ARV-110, ARV-471), validating the platform[16].
Key programs in development include:
Companies advancing targeted protein degradation include:
This novel modality offers unique advantages:
Significant challenges remain:
The therapeutic landscape for neurodegenerative diseases is evolving toward combination approaches that address multiple aspects of disease pathogenesis simultaneously. Just as combination therapy has transformed HIV/AIDS and cancer treatment, neurodegenerative disease therapy will likely require multi-target strategies[17].
Emerging strategies include:
Several emerging technologies may transform the field:
The future will likely see increased personalization:
Long, J. M., & Holtzman, D. M. (2019). Alzheimer disease: An update on pathobiology and treatment strategies. Cell. 2019. ↩︎
Karch, C. M., & Goate, A. M. (2015). Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biological Psychiatry. 2015. ↩︎
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019). A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nature Reviews Neurology. 2019. ↩︎
van Dyck, C. H., et al. (2023). Lecanemab in early Alzheimer's disease. The New England Journal of Medicine. 2023. ↩︎
Pagano, G., et al. [(2022)](https://doi.org/10.1016/S1474-4422(21). The Lancet Neurology. 2022. ↩︎
Hudry, E., & Cousin, O. (2022). Gene therapy for neurodegenerative diseases. Nature Reviews Disease Primers. 2022. ↩︎
Mendell, J. R., et al. (2017). Gene therapy for spinal muscular atrophy: Safety and early outcomes. Pediatrics. 2017. ↩︎
Rinaldi, C., & Wood, M. J. A. (2018). Antisense oligonucleotides: The next frontier for treatment of neurological disorders. Nature Reviews Neurology. 2018. ↩︎
Miller, T., et al. (2023). The New England Journal of Medicine. 2023. ↩︎
Ionis. (2023). IONIS-MAPTRx demonstrates dose-dependent reduction of tau protein in Phase 1/2 study. Ion is Pharmaceuticals Press Release. 2023. ↩︎
Cummings, J., et al. (2023). Alzheimer's & Dementia. 2023. ↩︎
Jennings, D., et al. [(2023)](https://doi.org/10.1016/S1474-4422(23). The Lancet Neurology. 2023. ↩︎
Athauda, D., et al. [(2017)](https://doi.org/10.1016/S0140-6736(17). The Lancet. 2017. ↩︎
Barker, R. A., et al. (2023). Human pluripotent stem cell-derived neurons for disease modeling and drug discovery: Progress and recommendations. Nature Reviews Neuroscience. 2023. ↩︎
Békés, M., Langley, D. R., & Crews, C. M. (2022). PROTAC targeted protein degraders: The past is prologue. Nature Reviews Drug Discovery. 2022. ↩︎
Mullard, A. (2024). FDA approves first targeted protein degrader. Nature Reviews Drug Discovery. 2024. ↩︎
Gaugler, J., et al. (2023). Journal of Alzheimer's Disease. 2023. ↩︎